Year: 2022

MONTREAL, Nov. 18, 2022 (GLOBE NEWSWIRE) — Dominion Water Reserves Corp. (“Dominion Water” or the “Corporation”) (CSE: DWR), is pleased to announce the results of its Annual General and Special Meeting (“AGSM”) held on November 18, 2022 and name change. The Corporation is pleased to report, that all items to be voted on at its AGSM were approved, as follows:the number of director was determined at six (6); the following individuals were elected as directors:Alexandre Côté, Robert Dunn, Olivier Primeau, Germain Turpin, Michael Pesner, and Raimondo MessinaMNP LLP, Chartered Accountants, was re-appointed as auditors, the by-laws of the Corporation was ratified and confirmed; and the corporate name change of the Corporation to “Prime Drink Group Corp. / Groupe Prime Drink Corp.”(the “Name Change”).Upon approval of the Name...

MONTREAL, Nov. 18, 2022 (GLOBE NEWSWIRE) — Nouveau Monde Graphite Inc. (“Nouveau Monde” or the “Company”) (NYSE: NMG, TSXV: NOU) announces the grant of 50,000 stock options to an officer. These stock options are granted in accordance with the terms of the stock option plan of the Company. Each option entitles the holder thereof to purchase one common share of the Company at a price of $6.48 per common share for a period expiring on November 13, 2027. These options shall vest in four equal installments every three months following the grant date. About Nouveau Monde Nouveau Monde is striving to become a key contributor to the sustainable energy revolution. The Company is working towards developing a fully integrated source of carbon-neutral battery anode material in Québec, Canada for the growing lithium-ion and fuel cell markets....

All amounts expressed in US dollars TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) (“Barrick,” the “Company” or the “Offeror”) today announced the pricing terms of its previously announced tender offer (the “Offer”) to purchase for cash any and all of its 5.250% Notes due 2042 (the “Notes”). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 14, 2022 relating to the Notes (the “Offer to Purchase”) and the accompanying notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Tender Offer Documents”). Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Set forth in the table below is the Total Consideration...

VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) — VITAL BATTERY METALS INC. (the “Company” or “Vital”) (CSE: “VBAM”) (FSE: “C0O”) (OTCQB: “VBAMF”) is pleased to announce that it has been approved for trading on the OTCQB Venture Market (“OTCQB”) effective November 18, 2022. The shares trade on the OTCQB under trading symbol “VBAMF”. The Company’s shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “VBAM” as well as the Frankfurt Stock Exchange (FSE) under the symbol “C0O”. This U.S. listing will provide the Company with access to a broader base of U.S. and international retail and institutional investors, ultimately providing investors with increased access to data, transparency and liquidity. Investors can find real-time quotes and market information for the Company...

– Delisting of REMS Patent sets path to potentially accelerate final approval by FDA DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the United States District Court for the District of Delaware (the “Delaware Court”) ordered Jazz Pharmaceuticals to delist U.S. Patent No. 8731963 (the “REMS Patent”) from the U.S. Food and Drug Administration’s (“FDA”) Orange Book. With this decision, Avadel seeks to accelerate the FDA’s final approval decision for LUMRYZ™, a once-at-bedtime investigational formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. “We are pleased with the court’s decision in favor of delisting...